The relationship between the presence of antibody to hepatitis B core antigen (anti-HBc) in donor blood and the development of hepatitis in recipients of that blood was studied in 6293 blood donors and 481 recipients who were followed for 6 to 9 months after transfusion. THE INCIDENCE OF transfusion-associated type B hepati tis has been reduced markedly by the exclusion of com mercial blood donors and the introduction of routine do nor screening for the hepatitis B surface antigen (HBsAg) (1-3), but some cases of type B hepatitis con tinue to occur. Antibody to hepatitis B core antigen (anti-HBc) has been long recognized to be a sensitive indicator of hepatitis B virus infection (4-7), and it has been suggested that testing donors for anti-HBc might enhance detection of those harboring low levels of this virus (4, 5; 8-10). Although an association between do nor anti-HBc status and the development of hepatitis B virus infection in a recipient is not unexpected, a surpris ing finding has been the report by the Transfusion-Trans mitted Viruses Study Group (11) of a significant associa tion between donor anit-HBc status and recipient non-A,
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non-B hepatitis. The reported incidence of transfusion-'| associated hepatitis in the United States ranges from' 5.4% to 27.1% (12), and greater than 90% of cases aiej, estimated to be related to the agent (s) designated non-A,^ non-B (13). No confirmed, specific test suitable for J screening blood donors for the non-A, non-B agent (s)?
| has yet been established. The Transfusion-Transmitted/'I Viruses Study has suggested that because of the similartH modes of transmission of hepatitis B and the non-A, nori=f| B virus, screening for anti-HBc might serve indirectly toj| identify donors with epidemiologic risk factors that ^ would enhance transmission of both agents. The present? study, which was conducted simultaneously with, but in-J™ dependency of, the Transfusion-Transmitted Viruses | Study, further investigates the association of anti-HBc in| donor blood and the development of transfusion-associat-V| ed hepatitis.
Materials and Methods
** The details of the prospective study design have been report-^ ed previously (13). Briefly, 729 consecutive adult patientSI undergoing open-heart surgery at the Clinical Center of the^ National Institutes of Health from November 1973 through _ cember 1980 were entered into the study and prospectively f«\J lowed for 6 to 9 months. Patients with HBsAg or transaminaw elevations before transfusion were excluded. Blood samples^ were obtained weekly or biweekly during the first 3 montnSj after transfusion, monthly for the next 3 months, and a final sample was obtained at 9 months. In addition to the study ulation, a control population of 203 patients undergoing car r$: catheterization without transfusions was similarly followed determine the frequency of hepatitis and hepatitis B seroconvi sion in hospitalized patients undergoing invasive cardiac P-* r " dures without transfusions.
SEROLOGIC TESTS
All recipient specimens were assayed for alanine amino" " ferase (ALT), aspartate aminotransferase (AST), and biuru^ levels and for HBsAg (Ausria II; Abbott Laboratories, Nm Chicago, Illinois). Recipient ALT and AST levels were il mined by a three-point kinetic assay with a sequential co P er-controlled biochemical analyzer (SMAC). Hepatitis w ^ agnosed when between 2 and 26 weeks after transfusion, " -recipient ALT level exceeded 2.5 times the upper limit ° mal (110 IU/L) and when a repeat sample 1 or ®°5 e .»j/L5l| later was at least 2 times the upper limit of normal (88 $ included from study (n = 248) Total (n = 729)
refers to the number of recipients. Patients were included or excluded according to the availability of samples from all donor blood units they had received, pistribution of specific hepatitis events within the included group as compared with distribution within the excluded grpup: chi square =2.18; degrees of Jttcdom = 3; P > 0 50 ( see tcxt for method). ^Included group as compared with excluded group in total events: chi square = 6.03; degrees of freedom = 1; p < 0.02 (see text for method).
_0ther nonviral causes of ALT elevation, such as drug toxicity, anesthesia, alcoholism, anoxia, shock, congestive heart failure, ind sepsis, were reasonably excluded. Hepatitis was considered jdenc when the serum bilirubin level exceeded 2.5 mg/dL. kt The samples from before and 3, 6, and 9 months after trans fusion were tested for antibody to HBsAg (anti-HBs) by radio immunoassay (AUSAB; Abbott Laboratories). The pretransfusidh and 3-and 6-month samples were also tested for anti-HBc ^ radioimmunoassay (CORAB, Abbott Laboratories) and, plen indicated by elevated ALT levels, for antibodies to cytogalovirus by indirect hemagglutination, Epstein-Barr virus immunofluorescence, and hepatitis A virus by radioixnmupissay (HAVAB, Abbott Laboratories). With the exception §3 paid apheresis donors whose platelets were transfused to atients, all blood donors were volunteers; only 2 of the 10 jfents receiving platelets from paid donors were among the [J patients included in the study analysis (see below). All tar blood products were negative for HBsAg by radioimmuBassay (AUSRIA II, Abbott Laboratories).
LASSIFICATION OF HEPATITIS
^ patients who developed ALT elevations consistent with msfusion-related viral hepatitis, the following criteria were JQ to define the cause of the hepatitis event. Type B hepatitis Sg diagnosed if the recipient developed HBsAg, or seroconjMried for anti-HBs or anti-HBc (or both) simultaneously with IP onset of ALT elevation. When anti-HBc or anti-HBs apKfcred in the 3-month sample, earlier samples were tested to pbnguish passive transfer of antibody from active formation ||he detected antibody. Hepatitis B virus seroconversion alone presented the de-novo appearance of anti-HBs or anti-HBc Kg? both) in the absence of ALT elevation. Cytomegalovirus fcpatitis was diagnosed when the hepatitis event was associated ith anticytomegalovirus antibody seroconversion and when ?* ere was no evidence for hepatitis B or hepatitis A virus infecoon. A rise in preexisting cytomegalovirus antibody titer was ttot considered evidence for an etiologic role for this agent. All available serum samples from donors, transfusion recipi ents, and untransfused patients were saved and stored at -20 to -70 °C. The present study involved retrieving donor serum samples and testing them for the presence of anti-HBs and antiHBc. Analysis of the relationship between donor anti-HBc and anti-HBs status and recipient hepatitis was restricted to those patients for whom all donor samples were available for testing, as indicated in Table 1 . Overall, blood samples from 6293 do nors to 481 recipients were assayed for anti-HBs and anti-HBc. The 481 recipients represented 66% of the total population. A subset of blood samples from 2549 donors was also tested for ALT with a kinetic assay on a biochromatic analyzer. The level of ALT in donor samples was considered elevated if it exceeded 53 IU/L, representing 2.25 SD above the mean log ALT level.
Using manufacturer's criteria for interpretation of the antiHBc qualitative (screening) test, we calculated a cutoff value by averaging the negative control mean and positive control mean. A 10% "gray zone" around the cutoff was then imposed to identify borderline results that required retesting in dupli cate. Specimens whose counts per minute were greater than 110% of the cutoff value were considered negative for antiHBc. Specimens with counts per minute lower than 90% of the cutoff value were considered positive for anti-HBc. Specimens whose rates fell within the 10% range of the cutoff value were retested in duplicate, and the three results were averaged to establish a definitive result.
STATISTICAL METHODS
The ordinary chi-square test (1 degree of freedom) was used to compare frequencies entered in 2 X 2 contingency tables. Kendall's V-statistic (14) was calculated to measure the strength of association between a pair of classifications. Fre quencies entered in larger contingency tables were compared with a chi-square test with an appropriate number of degrees of freedom. When statistical significance was found, partitioning of the chi-square statistic was applied to show the principal source of variation (15). When indicated, chi-square tests with multiple degrees of freedom were modified so as to assess the presence of linear trends in the proportion of positive findings (15). Association between quantitative variables was measured by the Spearman rank correlation coefficient (r s ). Student's ttest was used to compare means, and results were expressed as a p value.
Results

COMPARISON OF STUDY POPULATIONS
The hepatitis events of the included subpopulation (those with a complete set of donor samples available) and those of patients excluded from the analysis are com pared in Table 1 . No instance of hepatitis A or EpsteinBarr virus hepatitis occurred in this study. Cases of hepa titis were significantly (p < 0.02) overrepresented in the study population, although differences in inclusion among the various types of hepatitis events were not sta- : antibody to hepatitis B surface a tistically significant (p > 0.50). The reason for this appar ent selection is unknown but might have been due to a coincidental higher incidence of hepatitis during the study years when overall donor sample retention was maximal (r s = 0.76, p < 0.025). Demographic and sero logic characteristics of recipients included in the analysis were compared with those of recipients excluded from analysis; no significant difference in age, sex, or prior ex posure to hepatitis B virus was noted. Similarly, no sig nificant difference in age, sex, or prior hepatitis B virus exposure was noted for patients who did or did not re ceive anti-HBc-positive blood. Because availability of all donor samples was increasingly less likely for recipients with increasingly large numbers of donors, recipients ex cluded had a significantly higher transfusion volume than the recipients included in this study (15.7 and 13.1 do nors/recipients, respectively; p < 0.001, Student's ttest). Transfusion volume is considered separately in the Results section as an important independent variable in our analysis.
RELATIONSHIP OF DONOR ANTIBODY TO HEPATITIS B CORE ANTIGEN TO RECIPIENT HEPATITIS EVENTS
The proportions of recipients found to have non-A, non-B hepatitis, cytomegalovirus hepatitis, or a hepatitis B event are shown in Table 2 pi refers to the number of recipients. -0, each transfusion level, the incidence of hepatitis among recipients of anti-HBc-positive blood was compared with that among recipients of anti-HBc-negative blood i results were pooled in a weighted mean difference test. e of regression was performed with frequency of disease event as the dependent (or outcome) variable and number of units transfused as the independent variable; j Q. 3 for each of the six regression coefficients.
atitis was still that due to anti-HBc (present comJfed with absent, chi square = 8.16, 2 df, p < 0.025) as gposed that due to anti-HBs (present compared with I|ent, chi square = 2.37, 1 df, p = 0.12). Because doanti-HBs status was not associated with a higher inciof recipient hepatitis, subsequent analyses were re acted to donor anti-HBc status. |The data in Table 2 
RELATIONSHIP OF TRANSFUSION VOLUME TO RECIPIENT HEPATITIS EVENTS
The percentage of patients who developed non-A, non-B hepatitis, cytomegalovirus hepatitis, or a hepatitis B virus event did not change significantly as the transfusion volume increased in either recipients of anti-HBc-positive blood or in recipients of only anti-HBc-negative blood (see regression analysis, Table 3 ). Table 3 In Table 5 , if the data were classified according to do-'f nor ALT status first and then according to anti-HBc ! f status, a similar partition of the chi-square variability was obtained. The major contribution was still that due to' issues. The primary conlow for a reexamination of the cern expressed was that the determination of efficacy in the Transfusion-Transmitted Viruses Study involved a correction factor for the background incidence of hepati tis in the nontransfused control population which neces sitated exclusion from analysis of 31 cases of hepatitis or almost half the cases in one study arm. It was suggested that deletion from analysis of such a large number of cases might introduce a bias into the efficacy calculation. In our current study, the background incidence of hepati tis in the nontransfused population was sufficiently low (0.5%) that a correction for background was not neces sary. Our predicted efficacy for anti-HBc testing (43%) is similar to that obtained in the Transfusion-Transmitted Viruses Study and, hence, concern regarding the correc tion factor that was imposed appears to have been unjust ified.
The purported mechanism by which anti-HBc identi fies non-A, non-B carriers is that such carriers might be sequentially or concomitantly exposed to both hepatitis B and non-A, non-B viruses. If this were true, then donor status for anti-HBs, another sensitive serologic marker of past hepatitis B virus infection, should also correlate with the occurrence of non-A, non-B hepatitis in the recipient. This finding was not the case in the Transfusion-Trans mitted Viruses Study (11, 19) and was a second point of concern expressed in the editorial (18)."Our study con firms the lack of association between donor anti-HBs status and subsequent occurrence of non-A, non-B hepa titis in the recipient, and it suggests that the association of anti-HBc with the non-A, non-B carrier state may in volve more than the coincidental exposure to multiple hepatitis viruses. In this regard, it has been suggested that the non-A, non-B virus and the hepatitis B virus may have a common origin, as shown by the finding of hepati tis B virus DNA in the serum and liver tissue of some patients diagnosed as having non-A, non-B hepatitis (20) . The possibility of a direct relationship between the non-A, non-B and hepatitis B viruses, however, remains a controversial issue (21) .
A third concern in Alter and Holland's editorial (18) was that previous studies of the relationship between do nor ALT level and recipient hepatitis (16, 17) and the more recent Transfusion-Transmitted Viruses Study analysis of anti-HBc (11) represented predictions of effi cacy based on the assumption that the anti-HBc-positive or ALT-elevated donor in any given case was the donor to transmit hepatitis and that exclusion of that particular donor would have prevented the ensuing hepatitis. The editorial stressed that predicted efficacy was not the equivalent of established efficacy and recommended that these predictions be tested in a randomized, prospective, controlled trial which compared directly the incidences of hepatitis after the receipt of blood tested and untested for ALT and anti-HBc. However, it has become increas ingly unlikely that such a study will ever be initiated. The anticipated reduction in the incidence of transfusion-related hepatitis as an indirect consequence of donor testing for antibody to the human T-lymphotropic virus type III and other trends in blood donation practice would neces sitate a substantial increase in the number of study par ticipants to confirm the predicted efficacy of anti-HBc testing. The consequent increased time, cost, and com plexity of such a study do not appear to be logistically, financially, and perhaps ethically feasible in the perspec tive of current research priorities.
A fourth concern was that the presence of anti-HBc and the presence of an elevated ALT level behaved as independent variables, even though both appear to serve as surrogate markers for the non-A, non-B carrier state. This lack of concordance, first noted by the TransfusionTransmitted Viruses Study (11), has been confirmed by our finding of virtual independence between the outcome of the two tests (Kendall's V = 0.03). Although most donors were both anti-HBc negative and had a normal ALT level, donors who were positive for anti-HBc only rarely had an elevated ALT level (3 of 103). If, indeed, the ALT and anti-HBc tests are detecting distinct popu lations of non-A, non-B virus carriers, then the potential impact of adopting indirect screening measures would be greatly magnified.
In the absence of a prospective controlled study, the existing database must be used to decide whether or not to adopt the ALT test, the anti-HBc test, or both. In considering these options, we must keep in perspective the surrogate nature of both assays. Both have a relative ly low level of predicted efficacy in preventing non-A, non-B hepatitis, and 60% to 70% of non-A, non-B trans fusion-associated hepatitis will probably continue to occur despite implementation of either of these tests. Equally disturbing, both tests have a high rate of false positivity: 70% to 88% of recipients of blood with antiHBc or an elevated ALT level do not develop non-A, non-B hepatitis (11, 16, 17) , and approximately 60% of donors with elevated ALT levels have nonviral factors as the most likely cause of their transaminase elevation (22) . An additional major concern is the resultant loss of blood donors, estimated to be 1% to 3% for ALT eleva tions and 4% to 8% for anti-HBc (11, 16, 17, 23) . In this discussion we do not wish to deal with the relative merits of one surrogate marker over the other, but rather to deal with the key issue of whether to adopt any indirect screening measure for detection of the non-A, non-B vi rus carrier state. Two important variables enter into this decision: the likelihood that a specific test for the non-A, non-B virus carrier state will become available in the near future, and the clinical significance of non-A, non-B hep atitis. Despite numerous reports of putative non-A, non-B assays, none has been independently confirmed (24), none has been able to distinguish proven non-A, non-B infectious sera from noninfectious control sera in coded panels (25) , and none has withstood the test of time. Currently, no specific assay is available for the agent(s) of non-A, non-B hepatitis, and none appears imminent; anticipation of specific assays should not defer the ne^ for a prompt decision regarding the adoption of surrogatetests.
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The severity of non-A, non-B hepatitis has been a con«> troversial issue. The disease tends to be mild at onset,* with only a quarter of patients being jaundiced and with other clinical symptoms being generally minor ( 
